NCT00150722View on ClinicalTrials.gov

High-Density Lipoprotein (HDL) Modulation and Endothelial Function

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Atherosclerosis
Interventions
DRUG

atorvastatin (or other tolerated statin + Niaspan/placebo)

atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over

Trial Locations (1)

T2N 2T9

Foothills Medical Centre, Calgary

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Ontario

OTHER

lead

University of Calgary

OTHER

NCT00150722 - High-Density Lipoprotein (HDL) Modulation and Endothelial Function | Biotech Hunter | Biotech Hunter